Danish Medicines Council makes five recommendations after April meeting
The council has processed five drug applications at this month’s meeting, including proposals from Bristol Meyers Squibb and Novartis, which received thumbs-up for treatments for cancer and spinal arthritis, respectively. Sanofi’s application was rejected and Merck/Pfizer’s combination pitch was not approved, despite new data.
by albert rønning-andersson, translated by daniel pedersen
Wednesday brought bad news for pharmaceutical firms Merck, Pfizer and Sanofi.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Medicines Council considers fast-track scheme
For subscribers
.jpg&w=384&q=75)
